Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2019. The document serves as a transaction notification regarding insider trading activity rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific securities transaction.
Material Changes and Transaction Details
The filing discloses a sale of Ordinary Shares by a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR).
- Transaction Date: November 1, 2019
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
- Transaction Type: Sale
- Volume: 8,200 shares
- Price: £17.54 per share
- Location: London Stock Exchange (XLON)
- Individual Involved: Ms Denise Connor (PCA of Mr Roger Connor, President, Global Vaccines)
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a share sale.
Investor Verification Checklist
- Verify the total number of shares held by Ms Denise Connor and Mr Roger Connor post-transaction.
- Confirm if this transaction was part of a pre-arranged trading plan.
- Review the broader market context for GSK shares on November 1, 2019, to assess the significance of the £17.54 sale price.